Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7420864 | 0.98 | GPR119 (0.58) | GPR119FAAHKDM4EPKMHPGD | |
| SCHEMBL7692137 | 0.98 | GPR119 (0.58) | GPR119FAAHKDM4EPKMHPGD | |
| SCHEMBL561013 | 0.95 | GPR119 (0.54) | GPR119FAAHKDM4EPKMHPGD | |
| SCHEMBL561360 | 0.89 | HPGD (0.53) | GPR119FAAHKDM4EPKMHPGD | |
| SCHEMBL15085741 | 0.89 | GPR119 (0.59) | GPR119FAAHKDM4EPKMHPGD | |
| SCHEMBL11980483 | 0.88 | GPR119 (0.48) | GPR119FAAHKDM4EPKMHPGD | |
| SCHEMBL1576008 | 0.86 | GPR119 (0.56) | GPR119FAAHKDM4EPKMHPGD | |
| SCHEMBL7512359 | 0.86 | GPR119 (0.56) | GPR119FAAHKDM4EPKMHPGD | |
| SCHEMBL16213130 | 0.85 | GPR119 (0.53) | GPR119FAAHKDM4EPKMHPGD | |
| SCHEMBL23499817 | 0.85 | GPR119 (0.57) | GPR119FAAHKDM4EPKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120092003-A | CDK protein degrading agents, pharmaceutical compositions and therapeutic uses | 拜欧斯瑞克斯公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
| US-11685717-B2 | Polypeptide integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685717-B2 | Polypeptide integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
| US-11643393-B2 | Integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643393-B2 | Integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| EP-0750610-A1 | PIPERIDYL-4-SUBSTITUTED THYROSINE DERIVATIVES AS SCINTIGRAPHIC IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOSIS | Diatide, Inc. (US) | 1997-01-02 | — | — | EP | disclosed |
| EP-0743302-A2 | Sulfonamide fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1996022288-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1995025720-A1 | PIPERIDYL-4-SUBSTITUTED THYROSINE DERIVATIVES AS SCINTIGRAPHIC IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOSIS | DIATECH, INC. (US) | 1995-09-28 | — | — | WO | disclosed |
| US-5358956-A | Anticoagulant | MERCK & CO., INC. (US) | 1994-10-25 | — | — | US | disclosed |
| US-5292756-A | Novel sulfonamide fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1994-03-08 | — | — | US | disclosed |
| WO-1993019046-A1 | NOVEL SULFONAMIDE FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1993-09-30 | — | — | WO | disclosed |
| WO-1993016697-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1993-09-02 | — | — | WO | disclosed |
| US-5227490-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0478363-A2 | Novel sulfonamide fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685717-B2 | Polypeptide integrin antagonists | ITGA2B, ITGAV, ITGB2 | GPR119 1026/4885FAAH 4686/4885KDM4E 4800/4885 |
| US-11643393-B2 | Integrin antagonists | ITGA2B, ITGA2, ITGB2 | GPR119 891/4885FAAH 4641/4885KDM4E 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.